Northstrive Biosciences has launched Phase II of its AI-driven development initiative in collaboration with Yuva Biosciences. This phase focuses on using MitoNova, an artificial intelligence platform developed by YuvaBio, to identify small molecule candidates that can enhance mitochondrial function, particularly in combating obesity and cardiac diseases.
The collaboration aims to virtually screen an extensive collection of drug-like small molecules through MitoNova. This process will predict which compounds have the highest potential to benefit mitochondrial health. Following the screening, YuvaBio will evaluate the chemical and bioactivity characteristics of the top candidates to identify promising ones for further biological testing.
YuvaBio plans to create a preliminary list of synthetic compounds designed for muscle preservation and boosting metabolic health. Northstrive Biosciences, operating under PMGC (ELAB, Financial) Holdings, is dedicated to the innovation and acquisition of leading-edge aesthetic medicines.
